After a personal journey and interest in Alzheimer's Disease (AD) by Bill Gates, Gates Ventures set out to find the best way to accelerate innovation in the field of AD. In partnership with the Alzheimer's Drug Discovery Foundation, Gates Ventures created the Diagnostics Accelerator (DxA) to fund innovations as a venture philanthropy fund. The AD field had seen rapid advances in therapeutics, and as such, large corporations were hesitant to take venture funding which meant potentially losing control and having other opinions on the Board. Instead, these companies were turning to other non-dilutive sources of funding. The DxA, and GV, sat at a crossroads and needed to determine where to go next to fulfill their mission.